Alnylam Pharmaceuticals Inc (ALNY)
NASDAQ · Healthcare · Biotechnology
Alnylam Pharmaceuticals Inc is a Healthcare company with a market capitalization of $30.70B and a trailing P/E ratio of 40.0.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | April 30, 2026 | $1.99 | $1.47 | +35.4% |
| Q4 2025 | February 12, 2026 | $1.25 | $1.50 | -16.7% |
| Q3 2025 | October 30, 2025 | $2.90 | $1.75 | +65.7% |
| Q2 2025 | July 31, 2025 | $0.32 | $0.15 | +113.3% |
| Q1 2025 | May 1, 2025 | $-0.01 | $-0.37 | +97.3% |
| Q4 2024 | February 13, 2025 | $0.06 | $-0.14 | +142.9% |
Short Interest
FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.
| Settlement | Shares Short | % of Shares Out | Days to Cover | Change |
|---|---|---|---|---|
| July 15, 2026 | 5,773,373 | 4.18% | 3.2 | -0.5% |
| June 30, 2026 | 5,799,788 | 4.20% | 4.2 | +6.7% |
| June 15, 2026 | 5,437,337 | 3.93% | 4.8 | +2.6% |
| May 29, 2026 | 5,300,015 | 3.83% | 5.8 | -1.8% |
| May 15, 2026 | 5,398,804 | 3.91% | 5.1 | +13.1% |
| April 30, 2026 | 4,773,214 | 3.45% | 4.0 | -5.2% |
| April 15, 2026 | 5,034,063 | 3.69% | 5.1 | -0.4% |
| March 31, 2026 | 5,056,408 | 3.71% | 4.0 | +15.7% |
Other Biotechnology Stocks
Frequently Asked Questions
What is Alnylam Pharmaceuticals Inc's market cap?
As of August 13, 2026, Alnylam Pharmaceuticals Inc (ALNY) has a market capitalization of $30.70B.
What is Alnylam Pharmaceuticals Inc's P/E ratio?
Alnylam Pharmaceuticals Inc trades at a trailing price-to-earnings (P/E) ratio of 40.0. Its forward P/E is 26.4.
Does Alnylam Pharmaceuticals Inc pay a dividend?
Alnylam Pharmaceuticals Inc does not currently pay a dividend.
What sector is ALNY in?
Alnylam Pharmaceuticals Inc is in the Healthcare sector, specifically the Biotechnology industry.
What is Alnylam Pharmaceuticals Inc's short interest?
As of the July 15, 2026 FINRA settlement, 5,773,373 ALNY shares were sold short, or 4.18% of shares outstanding. Days to cover: 3.2. FINRA publishes short interest twice a month, about nine business days after each settlement date.
What was Alnylam Pharmaceuticals Inc's revenue?
In its latest reported fiscal year (ending December 31, 2025), Alnylam Pharmaceuticals Inc reported revenue of $3.71B and net income of $313.75M.
Ask your own questions about ALNY
Try mrmarket.ai freeData as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.